SAN JOSE, Calif.--(BUSINESS WIRE)--Reviva Pharmaceuticals, Inc., (Reviva), a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder. REFRESH is a randomized, double-blind, placebo-controlled, dose ranging, global and multi-center phase 2 study to assess the efficacy, safety and tolerability of RP5063 in male and female patients with schizophrenia. A total of 234 schizophrenia patients were enrolled from USA, Asia and Europe in this phase 2 study (for more details please visit: www.clinicaltrials.gov and identifier: NCT01490086). These top-line results will be followed with more details following completion of the data analysis at New Clinical Drug Evaluation Unit (NCDEU) annual meeting on May 28-31, 2013. An earlier Phase 1b trial had been conducted in patients with stable schizophrenia in the United States reported at NCDEU 2012.
